Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adrenal Insufficiency × 30 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 420 Carcinoma, Non-Small-Cell Lung 349 Neoplasms 324 Prostatic Neoplasms 290 Colorectal Neoplasms 220 Lung Neoplasms 211 Neoplasm Metastasis 190 Leukemia, Myeloid, Acute 183 Multiple Myeloma 172 Ovarian Neoplasms 159 Melanoma 145 Pancreatic Neoplasms 124 Squamous Cell Carcinoma of Head and Neck 117 Recurrence 108 Brain Neoplasms 100 Glioblastoma 99 Triple Negative Breast Neoplasms 98 Carcinoma, Hepatocellular 95 Lymphoma 93 Uterine Cervical Neoplasms 91 Stomach Neoplasms 90 Glioma 90 Endometrial Neoplasms 90 Precursor Cell Lymphoblastic Leukemia-Lymphoma 88 Urinary Bladder Neoplasms 87 Carcinoma, Renal Cell 87 Lymphoma, Non-Hodgkin 80 Myelodysplastic Syndromes 76 Lymphoma, Follicular 75 Sarcoma 74

Interventions

ravulizumab 1 Prednisone 1 Prednisolone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07221838 2026-03-03

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Not yet recruiting

Adrenal Insufficiency, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡